Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Linden

Showing results (361-370 of 409) with videos related to

Pageof 41
Sort By:
Cell Death and Differentiation|July 13, 2000
Selective localization of Bcl-2 to the inner mitochondrial and smooth endoplasmic reticulum membranes in mammalian cellsT Gotow, M Shibata, S Kanamori, et al.
Cancer|January 8, 2005
Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survivalLisa K Dunnwald, Julie R Gralow, Georgiana K Ellis, et al.
Clinical Breast Cancer|November 28, 2017
Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast CancerAmy E Chang, Qian V Wu, Isaac C Jenkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2016
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast CancerBrenda F Kurland, Lanell M Peterson, Jean H Lee, et al.
Breast Cancer Research : BCR|February 18, 2025
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancerNatasha B Hunter, Lanell M Peterson, Jennifer M Specht, et al.
Chemical Science|June 17, 2026
Lipids and lipid nanoparticles functionalized with randomized poly(ethylene glycol) (rPEG) for mRNA deliveryPhilip Dreier, Caroline Bockhard, David Seibel, et al.
Oncology Reports|May 21, 2011
P53 gene alterations in differentiated thyroid cancersM Herrmann, D Baunoch, M Maliarik, et al.
Clinical Breast Cancer|May 31, 2015
Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is NewEunpi Cho, Ann K Schwemm, Lena M Rubinstein, et al.
Nuclear Medicine and Biology|October 9, 2007
Challenges in clinical studies with multiple imaging probesKenneth A Krohn, Finbarr O'Sullivan, John Crowley, et al.
Breast Cancer Research and Treatment|February 3, 2007
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)Jennifer M Specht, Stephen L Tam, Brenda F Kurland, et al.
Pageof 41

Showing results (361-370 of 409) with videos related to

Sort By:
Pageof 41
Cell Death and Differentiation|July 13, 2000
Selective localization of Bcl-2 to the inner mitochondrial and smooth endoplasmic reticulum membranes in mammalian cellsT Gotow, M Shibata, S Kanamori, et al.
Cancer|January 8, 2005
Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survivalLisa K Dunnwald, Julie R Gralow, Georgiana K Ellis, et al.
Clinical Breast Cancer|November 28, 2017
Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast CancerAmy E Chang, Qian V Wu, Isaac C Jenkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2016
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast CancerBrenda F Kurland, Lanell M Peterson, Jean H Lee, et al.
Breast Cancer Research : BCR|February 18, 2025
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancerNatasha B Hunter, Lanell M Peterson, Jennifer M Specht, et al.
Chemical Science|June 17, 2026
Lipids and lipid nanoparticles functionalized with randomized poly(ethylene glycol) (rPEG) for mRNA deliveryPhilip Dreier, Caroline Bockhard, David Seibel, et al.
Oncology Reports|May 21, 2011
P53 gene alterations in differentiated thyroid cancersM Herrmann, D Baunoch, M Maliarik, et al.
Clinical Breast Cancer|May 31, 2015
Adjuvant Metronomic CMF in a Contemporary Breast Cancer Cohort: What's Old Is NewEunpi Cho, Ann K Schwemm, Lena M Rubinstein, et al.
Nuclear Medicine and Biology|October 9, 2007
Challenges in clinical studies with multiple imaging probesKenneth A Krohn, Finbarr O'Sullivan, John Crowley, et al.
Breast Cancer Research and Treatment|February 3, 2007
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)Jennifer M Specht, Stephen L Tam, Brenda F Kurland, et al.
Pageof 41